Phosphorus binders: The new and the old, and how to choose

Cleve Clin J Med. 2018 Aug;85(8):629-638. doi: 10.3949/ccjm.85a.17054.

Abstract

In caring for patients with chronic kidney disease, it is important to prevent and treat hyperphosphatemia with a combination of dietary restrictions and phosphorus binders. This review describes the pathophysiology and control of hyperphosphatemia and the different classes of phosphorus binders with respect to their availability, cost, side effects, and scenarios in which one class of binder may be more beneficial than another.

Publication types

  • Review

MeSH terms

  • Chelating Agents / therapeutic use*
  • Humans
  • Hyperphosphatemia / etiology
  • Hyperphosphatemia / physiopathology*
  • Phosphorus / blood*
  • Renal Dialysis / adverse effects
  • Renal Insufficiency, Chronic / blood*
  • Renal Insufficiency, Chronic / complications
  • Renal Insufficiency, Chronic / therapy

Substances

  • Chelating Agents
  • Phosphorus